Screening method
View Patent ↗The screening method for a compound or a salt thereof that alters the binding property between Neuromedin U or a salt thereof and TGR-1 or a salt thereof, characterized by using Neuromedin U, a derivative thereof or a salt thereof and TGR-1 or a salt thereof, can be useful for screening a therapeutic and/or prophylactic agent for hypertension and stress-related diseases, etc. A TGR-1 antagonist can be useful as a therapeutic and/or prophylactic agent for hypertension and stress-related diseases, etc.
1. A method for screening for a compound or a salt thereof that alters the binding property of Neuromedin U or a salt thereof with a protein or a salt thereof of amino acid sequence SEQ ID NO:1 or SEQ ID NO:21, comprising the steps of:
a) measuring the binding of a labeled Neuromedin U with said protein or a salt thereof;
b) measuring the binding of a labeled Neuromedin U with said protein or a salt thereof in the presence of a test compound; and
c) comparing the results of steps a) and b).
2. The screening method according to claim 1 , wherein said Neuromedin U is a peptide of amino acid sequence SEQ ID NO:11.
3. A kit for screening for a compound or a salt thereof that alters the binding property of Neuromedin U or a salt thereof with a protein or a salt thereof of amino acid sequence SEQ ID NO:1 or SEQ ID NO:21, comprising:
Neuromedin U, a derivative thereof or a salt thereof; and
a protein or a salt thereof of amino acid sequence SEQ ID NO:1 or SEQ ID NO:21.
4. The screening kit according to claim 3 , wherein said Neuromedin U is a peptide of amino acid sequence SEQ ID NO:11.
5. A method for screening for a compound or a salt thereof that alters the binding property of Neuromedin U or a salt thereof with a protein or a salt thereof having an amino acid sequence at least about 90% homologous to SEQ ID NO:1 or SEQ ID NO:21 comprising the steps of:
a) measuring the binding of a labeled Neuromedin U with said protein or a salt thereof;
b) measuring the binding of a labeled Neuromedin U with said protein or a salt thereof in the presence of a test compound; and
c) comparing the results of steps a) and b)
wherein said protein or salt thereof are activated by Neuromedin U binding.
6. The method of claim 5 wherein said protein has an amino acid sequence at least about 95% homologous to SEQ ID NO:1 or SEQ ID NO:21.
7. The method of claim 5 wherein said protein has an amino acid sequence at least about 98% homologous to SEQ ID NO:1 or SEQ ID NO:21.
8. A kit for screening for a compound or a salt thereof that alters the binding property of Neuromedin U or a salt thereof with a protein or a salt thereof having an amino acid sequence at least about 90% homologous to SEQ ID NO:1 or SEQ ID NO:21 comprising:
Neuromedin U, a derivative thereof or a salt thereof; and
a protein or a salt thereof having an amino acid sequence at least about 90% homologous to SEQ ID NO:1 or SEQ ID NO:21 wherein said protein or salt thereof are activated by Neuromedin U binding.
9. The kit of claim 8 wherein said protein has an amino acid sequence at least about 95% homologous to SEQ ID NO:1 or SEQ ID NO:21.
10. The kit of claim 8 wherein said protein has an amino acid sequence at least about 98% homologous to SEQ ID NO:1 or SEQ ID NO:2.